Advantages of Activa Parkinson's Control Therapy

*Includes only patient data that were fully verified against medical records.Percentages have been rounded to the nearest whole percentage.

Activa Parkinson’s Control Therapy treats bilateral symptoms of Parkinson’s disease with bilateral stimulation using two systems—each consisting of a neurostimulator, an extension and a lead—all implanted under the patient's skin.

In Medtronic clinical studies, Activa Therapy reduced dyskinetic "on" time by an average of 2.8 hours in STN patients and 4.2 hours in GPi patients (data on file at Medtronic; includes only patient data that were fully verified against medical records):

References

1. Medtronic Activa Therapy Clinical Summary 2002, UC19990178 EN.
2. Data on file at Medtronic.
3. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord. 1998;13:406-413.

©Medtronic, Inc. 2008                                                   • Contact Medtronic • Privacy Statement • Terms of Use • Site Map